Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma

Autor: Beth Hahn, Jared Silver, Michael Bogart, E. Packnett, Juan Wu, Donna McMorrow

Publikováno v: Journal of Asthma and Allergy. 13:689-699

Background Patients with severe asthma often require oral corticosteroid (OCS) treatment. Clinical trials have demonstrated that mepolizumab can reduce OCS dependence, but real-world data are limited. Objective To evaluate the impact of mepolizumab o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3dba7918aa02ef0971a1c0b5f9410800
https://doi.org/10.2147/jaa.s275944

Zobrazit plný text záznamu

Prevalence and Frequency of Eosinophil (EOS) Testing in Patients with Asthma

Autor: T.C. Corbridge, A. Deb, E. Packnett, K. Jariwala-Parikh, M. Bogart

Publikováno v: A34. TOPICS IN HEALTH SERVICES RESEARCH AND SELF-MANAGEMENT FOR PATIENTS WITH OBSTRUCTIVE LUNG DISEASE.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::da6f9cf8131cdb0762afc96f82df4ef1
https://doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1313

Zobrazit plný text záznamu

Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs

Autor: Michael Bogart, E. Packnett, Christopher F. Bell, Hector Ortega, Jean-Pierre Llanos, Janna Manjelievskaia, Beth Hahn

Publikováno v: BASE-Bielefeld Academic Search Engine

Rationale Results from clinical trials in patients with severe eosinophilic asthma have demonstrated that mepolizumab is well tolerated and is associated with improved asthma control as evidenced by reductions in both exacerbations and maintenance or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c8a11aac5cbabeb9b7206b86679f875
https://doi.org/10.2147/jaa.s236609

Zobrazit plný text záznamu

EPH171 Delivery Outcomes in the United States Among Women With Commercial or Medicaid Insurance During the COVID-19 Pandemic

Autor: B Brady, E Packnett, LA Palmer

Publikováno v: Value in Health. 25:S224

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::24c0357cc02bd94e20e33e206f5cbe3b
https://doi.org/10.1016/j.jval.2022.09.1092

Zobrazit plný text záznamu

EE433 A US Claims Database Analysis of the Impact of Fremanezumab on Migraine-Related Health Care Utilization and Costs in Patients with Common Comorbidities, Acute Medication Overuse, or Difficult-to-Treat Migraine

Autor: DC Buse, MT Driessen, LJ Krasenbaum, MJ Seminerio, K Carr, M Ortega, E Packnett

Publikováno v: Value in Health. 25:S419-S420

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b356ca9e67a408835a01f4dea8851454
https://doi.org/10.1016/j.jval.2022.04.681

Zobrazit plný text záznamu

A real-world study of inhaled corticosteroid use in patients with severe eosinophilic asthma treated with mepolizumab

Autor: Nestor A. Molfino, Jonathan Corren, Michael Bogart, Jared Silver, E. Packnett, Juan Wu, Donna McMorrow, Beth Hahn

Publikováno v: Annals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology. 128(2)

Background Mepolizumab is a humanized anti–interleukin-5 monoclonal antibody approved for the treatment of patients with severe eosinophilic asthma (SEA). There is limited evidence that patients treated with mepolizumab can reduce inhaled corticost

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0636d244c5717f898551ca0df2cb0e64
https://pubmed.ncbi.nlm.nih.gov/34774737

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání